On March 2, 2020 Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on harnessing the body’s immune system in the fight against cancer, reported that data related to Anixa’s recently launched Cchek Prostate Cancer Confirmation test (Cchek PCC) will be presented at the "AI and Big Data in Cancer: From Innovation to Impact" conference (Press release, Anixa Biosciences, MAR 2, 2020, View Source [SID1234555017]). Cchek is Anixa’s artificial intelligence (AI) driven cancer detection technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The "AI and Big Data in Cancer" conference takes place March 29-31, 2020 at the Westin Boston Waterfront in Boston, Massachusetts and is designed to accelerate the implementation of AI in oncology care. The conference will showcase the impact the technology has had on diagnosis, treatment decisions and patient care and illustrate how technology, data and analytics innovations can be translated into clinical practices. The meeting will be attended by researchers, academics, clinicians, technologists, entrepreneurs, regulators and insurance payers.
Details of the presentation are as follows:
Abstract title: Using artificial intelligence to detect prostate cancer – how a flow cytometry-based liquid biopsy assay can help reduce the number of unnecessary prostate biopsies performed each year
Authors: George Dominguez, PhD, John Roop, Anthony Campisi, Amit Kumar, PhD
Presenting Author: George Dominguez, PhD
Poster Number: P.14
Room: Grand Ballroom C,D,E
Presentation Dates and Times: Sunday, March 29, 2020 (6:00 PM – 7:00 PM)
Monday, March 30, 2020 (1:00 PM – 2:00 PM)
Tuesday, March 31, 2020 (1:00 PM – 2:00 PM)
About Cchek
Cchek is an early cancer detection technology, that measures a patient’s immunological response to a malignancy by analyzing immune system cells in peripheral blood. The goal is to utilize the technology to determine a patient’s cancer status from a simple blood draw, eliminating the need for a biopsy, which can be an expensive, painful and invasive procedure. Further, conventional methods using current cancer screening tests often lack accuracy and reliability. Anixa’s orthogonal approach using flow cytometry coupled with artificial intelligence provides an alternative method that offers improved affordability, efficacy and efficiency. To date, Anixa has successfully used Cchek to detect the presence of 20 different cancers including lung, colon, breast and prostate. The robust cancer detection performance of Cchek makes it a platform from which multiple cancer diagnostic tests may be developed. In December 2019, Anixa announced the commercial launch of the Cchek Prostate Cancer Confirmation test (Cchek PCC), the first test developed with the Cchek liquid biopsy technology.